Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Changhoon Yoo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1451-8455; OpenAlex author ID A5057947271, A5090754319, A5137144108. Sources: ClinicalTrials.gov.

Their work

Papers
50 (first author 3, last author 7)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
140
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 5 papers, 1 trial · 2020: 7 papers · 2021: 5 papers, 3 trials · 2022: 7 papers · 2023: 4 papers · 2024: 7 papers · 2025: 4 papers · 2026: 7 papers

Papers 50

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  3. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  4. ASO Author Reflections: Integrating Stereotactic Body Radiation into Modern Chemotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19848-y↗
  5. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  6. Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX. Co-author DOI 10.3389/fonc.2026.1762299↗
  7. Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy. Co-author DOI 10.3390/ijms27198668↗
  8. Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, It… Co-author DOI 10.1016/j.esmogo.2025.100217↗
  9. Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning. Co-author DOI 10.1200/cci-25-00124↗
  10. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  11. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  12. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  13. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Last author DOI 10.1016/j.ejca.2024.114194↗
  14. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Last author DOI 10.1016/j.pan.2024.02.004↗
  15. Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. Co-author DOI 10.1080/00365521.2024.2414804↗
  16. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  17. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Co-author DOI 10.2217/fon-2023-0963↗
  18. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  19. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  20. PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis. Co-author DOI 10.21873/anticanres.16754↗
  21. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  22. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Last author DOI 10.4143/crt.2023.452↗
  23. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  24. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIR… Last author DOI 10.1016/j.esmoop.2022.100484↗
  25. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. First author DOI 10.1177/17588359221097190↗
  26. Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. Last author DOI 10.21037/cco-21-166↗
  27. Impact of Baseline Muscle Mass and Myosteatosis on the Development of Early Toxicity During First-Line Chemotherapy in Patients With Initially Metastatic Pancr… Co-author DOI 10.3389/fonc.2022.878472↗
  28. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism i… First author DOI 10.3390/cancers14030559↗
  29. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  30. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  31. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  32. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicent… Co-author DOI 10.1016/j.esmoop.2021.100049↗
  33. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  34. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventiona… Last author DOI 10.1177/17588359211003053↗
  35. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  36. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  37. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcin… Last author DOI 10.1177/1758835920923424↗
  38. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  39. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  40. EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.3390/jcm9061666↗
  41. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  42. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammat… Co-author DOI 10.1007/s10637-018-0681-y↗
  43. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
  44. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  45. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13206↗
  46. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  47. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. First author DOI 10.1007/s10637-017-0497-1↗
  48. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  49. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  50. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗

Trials 4

  1. Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma Principal investigator NCT04662112↗
  2. mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma Principal investigator NCT04986930↗
  3. Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer Principal investigator NCT05083780↗
  4. Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer Principal investigator NCT04133155↗

Closest collaborators

The 25 strongest of 140 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu‐pyo Kim · 34 shared papers, 2017–2026 · strength 4.65
  2. Baek‐Yeol Ryoo · 26 shared papers, 2017–2026 · strength 3.23
  3. Dae Wook Hwang · 24 shared papers, 2017–2026 · strength 3.18
  4. Song Cheol Kim · 24 shared papers, 2017–2026 · strength 3.12
  5. Ki Byung Song · 18 shared papers, 2017–2026 · strength 2.10
  6. Tae Jun Song · 16 shared papers, 2017–2026 · strength 1.86
  7. Jin‐hong Park · 13 shared papers, 2017–2026 · strength 1.52
  8. Do Hyun Park · 14 shared papers, 2017–2024 · strength 1.52
  9. Seung Soo Lee · 9 shared papers, 2020–2026 · strength 1.49
  10. Sang Soo Lee · 14 shared papers, 2017–2024 · strength 1.40
  11. Seung‐Mo Hong · 9 shared papers, 2018–2025 · strength 1.37
  12. Dong Wan Seo · 11 shared papers, 2017–2025 · strength 1.31
  13. Dongwook Oh · 8 shared papers, 2020–2026 · strength 1.30
  14. Woohyung Lee · 9 shared papers, 2020–2026 · strength 1.24
  15. Jae Ho Byun · 8 shared papers, 2020–2025 · strength 1.24
  16. Jin Hee Kim · 8 shared papers, 2020–2025 · strength 1.24
  17. Hyehyun Jeong · 6 shared papers, 2020–2026 · strength 1.22
  18. Hyoung Jung Kim · 7 shared papers, 2020–2025 · strength 1.15
  19. Yejong Park · 7 shared papers, 2019–2024 · strength 0.96
  20. Dong‐Wan Seo · 7 shared papers, 2018–2025 · strength 0.95
  21. So Heun Lee · 5 shared papers, 2022–2026 · strength 0.95
  22. Jong Keon Jang · 5 shared papers, 2021–2025 · strength 0.91
  23. Dilmurodjon Eshmuminov · 4 shared papers, 2023–2026 · strength 0.81
  24. Víctor López‐López · 4 shared papers, 2023–2026 · strength 0.81
  25. Bong Jun Kwak · 5 shared papers, 2022–2024 · strength 0.78

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.